BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BG1805 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BG1805\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06118788-2871@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BG1805: Phase 1/2 readout est. (NCT06118788)
DESCRIPTION:BG1805\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase I Cl
 inical Study: BG1805 Injection in the Treatment of Relapsed or Refractory 
 Acute Myeloid Leukemia\nEstimated primary completion: March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bg1805#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06118788
URL:https://assetmemo.bio/drug/bg1805#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06347458-2871@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BG1805: Phase 1 readout est. (NCT06347458)
DESCRIPTION:BG1805\, phase 1\, Acute Myeloid Leukemia.\nStudy: BG1805 Injec
 tion in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in 
 Children\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bg1805#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06347458
URL:https://assetmemo.bio/drug/bg1805#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
